OraSure Q4 Revenue Tops Guidance, Reports $19.3M Loss, Eyes 2026 Test Launches
OraSure reported Q4 revenue of $26.8 million, topping its guidance midpoint despite a 29% year-over-year drop in net sales. The firm logged a $19.3 million GAAP net loss, affirmed its $40 million share repurchase plan and expects 2026 rapid molecular test and Colli-Pee™ device launches pending U.S. regulatory clearances.
1. Q4 Financial Results
OraSure delivered Q4 revenue of $26.8 million, above the midpoint of its guidance range but down 29% year-over-year. Core business revenue of $26.7 million reflected diagnostic and sample management solutions, while legacy COVID-19 and other services contributed negligible sales, yet gross margin improved to 41.0%.
2. Profitability and Loss
The company recorded a GAAP net loss of $19.3 million, or $0.27 per share, versus a $10.8 million loss a year earlier. Non-GAAP net loss amounted to $13.6 million, driven by sustained R&D and SG&A investments to support new product development.
3. Product Pipeline and Outlook
OraSure plans U.S. regulatory clearance and launches of its rapid molecular self-test for chlamydia and gonorrhea, plus the Colli-Pee™ at-home urine collection device in 2026. Management believes these innovations will advance its strategy to decentralize diagnostics and expand accessible care.
4. Balance Sheet and Capital Return
With a strong balance sheet, OraSure continues disciplined investments in organic and inorganic growth while executing a $40 million share repurchase program. The buyback supports shareholder value despite ongoing earnings pressure.